falseQ100015228602022December 310.102838P2YP3Y00015228602022-01-012022-03-3100015228602022-05-09xbrli:shares00015228602022-03-31iso4217:USD00015228602021-12-31iso4217:USDxbrli:shares00015228602021-01-012021-03-310001522860us-gaap:PreferredStockMember2021-12-310001522860us-gaap:CommonStockMember2021-12-310001522860us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMember2021-12-310001522860us-gaap:RetainedEarningsMember2021-12-310001522860us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001522860us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001522860us-gaap:PreferredStockMember2022-01-012022-03-310001522860us-gaap:CommonStockMember2022-01-012022-03-310001522860us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMember2022-01-012022-03-310001522860us-gaap:RetainedEarningsMember2022-01-012022-03-310001522860us-gaap:PreferredStockMember2022-03-310001522860us-gaap:CommonStockMember2022-03-310001522860us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMember2022-03-310001522860us-gaap:RetainedEarningsMember2022-03-310001522860us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001522860us-gaap:CommonStockMember2020-12-310001522860us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMember2020-12-310001522860us-gaap:RetainedEarningsMember2020-12-310001522860us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-3100015228602020-12-310001522860us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001522860us-gaap:CommonStockMember2021-01-012021-03-310001522860us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMember2021-01-012021-03-310001522860us-gaap:RetainedEarningsMember2021-01-012021-03-310001522860us-gaap:CommonStockMember2021-03-310001522860us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMember2021-03-310001522860us-gaap:RetainedEarningsMember2021-03-310001522860us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-3100015228602021-03-3100015228602020-08-100001522860us-gaap:IPOMember2020-08-102020-08-100001522860us-gaap:OverAllotmentOptionMember2020-08-102020-08-100001522860us-gaap:IPOMember2020-08-1000015228602021-07-012021-07-310001522860us-gaap:OverAllotmentOptionMember2021-07-012021-07-310001522860us-gaap:OverAllotmentOptionMember2021-07-310001522860afib:PublicStockOfferingMember2021-07-012021-07-3100015228602021-01-012021-12-3100015228602020-01-012020-12-3100015228602020-07-282020-07-28xbrli:pureafib:segment0001522860afib:DeferredEquipmentAgreementsMember2022-01-012022-03-310001522860srt:MinimumMemberafib:DeferredEquipmentAgreementsMember2022-01-012022-03-310001522860srt:MaximumMemberafib:DeferredEquipmentAgreementsMember2022-01-012022-03-310001522860srt:MinimumMember2022-01-012022-03-310001522860srt:MaximumMember2022-01-012022-03-310001522860srt:MaximumMember2022-03-310001522860afib:DisposablesMember2022-01-012022-03-310001522860afib:DisposablesMember2021-01-012021-03-310001522860afib:SystemsMember2022-01-012022-03-310001522860afib:SystemsMember2021-01-012021-03-310001522860us-gaap:ProductAndServiceOtherMember2022-01-012022-03-310001522860us-gaap:ProductAndServiceOtherMember2021-01-012021-03-310001522860country:US2022-01-012022-03-310001522860country:US2021-01-012021-03-310001522860us-gaap:NonUsMember2022-01-012022-03-310001522860us-gaap:NonUsMember2021-01-012021-03-31afib:reportingUnit0001522860us-gaap:TaxYear2021Member2022-03-310001522860us-gaap:TaxYear2020Member2022-03-310001522860afib:CoronavirusAidReliefAndEconomicSecurityActMember2022-01-012022-03-310001522860afib:CoronavirusAidReliefAndEconomicSecurityActMember2022-03-310001522860us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2022-03-310001522860us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2022-03-310001522860us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2022-03-310001522860us-gaap:MoneyMarketFundsMember2022-03-310001522860us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMember2022-03-310001522860us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2022-03-310001522860us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMember2022-03-310001522860us-gaap:CorporateDebtSecuritiesMember2022-03-310001522860us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember2022-03-310001522860us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2022-03-310001522860us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMember2022-03-310001522860us-gaap:USTreasurySecuritiesMember2022-03-310001522860us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMember2022-03-310001522860us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2022-03-310001522860us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMember2022-03-310001522860us-gaap:CommercialPaperMember2022-03-310001522860afib:YankeeDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-03-310001522860afib:YankeeDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-03-310001522860afib:YankeeDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-03-310001522860afib:YankeeDebtSecuritiesMember2022-03-310001522860afib:SupranationalMemberus-gaap:FairValueInputsLevel1Member2022-03-310001522860afib:SupranationalMemberus-gaap:FairValueInputsLevel2Member2022-03-310001522860afib:SupranationalMemberus-gaap:FairValueInputsLevel3Member2022-03-310001522860afib:SupranationalMember2022-03-310001522860us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-03-310001522860us-gaap:FairValueInputsLevel2Memberus-gaap:AssetBackedSecuritiesMember2022-03-310001522860us-gaap:FairValueInputsLevel3Memberus-gaap:AssetBackedSecuritiesMember2022-03-310001522860us-gaap:AssetBackedSecuritiesMember2022-03-310001522860us-gaap:FairValueInputsLevel1Member2022-03-310001522860us-gaap:FairValueInputsLevel2Member2022-03-310001522860us-gaap:FairValueInputsLevel3Member2022-03-310001522860us-gaap:FairValueInputsLevel1Memberafib:ContingentConsiderationMember2022-03-310001522860us-gaap:FairValueInputsLevel2Memberafib:ContingentConsiderationMember2022-03-310001522860us-gaap:FairValueInputsLevel3Memberafib:ContingentConsiderationMember2022-03-310001522860afib:ContingentConsiderationMember2022-03-310001522860us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2021-12-310001522860us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2021-12-310001522860us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2021-12-310001522860us-gaap:MoneyMarketFundsMember2021-12-310001522860us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMember2021-12-310001522860us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2021-12-310001522860us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMember2021-12-310001522860us-gaap:CorporateDebtSecuritiesMember2021-12-310001522860us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember2021-12-310001522860us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2021-12-310001522860us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMember2021-12-310001522860us-gaap:USTreasurySecuritiesMember2021-12-310001522860us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMember2021-12-310001522860us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2021-12-310001522860us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMember2021-12-310001522860us-gaap:CommercialPaperMember2021-12-310001522860afib:YankeeDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-12-310001522860afib:YankeeDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2021-12-310001522860afib:YankeeDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2021-12-310001522860afib:YankeeDebtSecuritiesMember2021-12-310001522860afib:SupranationalMemberus-gaap:FairValueInputsLevel1Member2021-12-310001522860afib:SupranationalMemberus-gaap:FairValueInputsLevel2Member2021-12-310001522860afib:SupranationalMemberus-gaap:FairValueInputsLevel3Member2021-12-310001522860afib:SupranationalMember2021-12-310001522860us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-12-310001522860us-gaap:FairValueInputsLevel2Memberus-gaap:AssetBackedSecuritiesMember2021-12-310001522860us-gaap:FairValueInputsLevel3Memberus-gaap:AssetBackedSecuritiesMember2021-12-310001522860us-gaap:AssetBackedSecuritiesMember2021-12-310001522860us-gaap:FairValueInputsLevel1Member2021-12-310001522860us-gaap:FairValueInputsLevel2Member2021-12-310001522860us-gaap:FairValueInputsLevel3Member2021-12-310001522860us-gaap:FairValueInputsLevel1Memberafib:ContingentConsiderationMember2021-12-310001522860us-gaap:FairValueInputsLevel2Memberafib:ContingentConsiderationMember2021-12-310001522860us-gaap:FairValueInputsLevel3Memberafib:ContingentConsiderationMember2021-12-310001522860afib:ContingentConsiderationMember2021-12-310001522860us-gaap:FairValueInputsLevel3Memberafib:ContingentConsiderationMember2022-01-012022-03-310001522860afib:ContingentConsiderationMember2022-01-012022-03-310001522860us-gaap:FairValueInputsLevel3Memberafib:RhythmXienceMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2022-03-310001522860us-gaap:FairValueInputsLevel3Memberafib:RhythmXienceMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2021-12-310001522860us-gaap:FairValueInputsLevel3Membersrt:MinimumMemberus-gaap:MeasurementInputMaturityMemberafib:RhythmXienceMember2022-03-310001522860us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputMaturityMembersrt:MaximumMemberafib:RhythmXienceMember2022-03-310001522860us-gaap:FairValueInputsLevel3Membersrt:MinimumMemberus-gaap:MeasurementInputMaturityMemberafib:RhythmXienceMember2021-12-310001522860us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputMaturityMembersrt:MaximumMemberafib:RhythmXienceMember2021-12-310001522860us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputPriceVolatilityMemberafib:RhythmXienceMember2022-03-310001522860us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputPriceVolatilityMemberafib:RhythmXienceMember2021-12-310001522860afib:BiotroniksMember2020-01-012020-12-310001522860afib:BiotroniksMemberafib:SeriesDConvertiblePreferredStocksMember2020-01-012020-03-310001522860afib:BiotroniksMember2019-01-012019-12-310001522860afib:BiotroniksMemberus-gaap:IntellectualPropertyMember2019-07-012019-07-310001522860afib:BiotroniksMember2019-07-012019-07-310001522860afib:BiotroniksMembersrt:MaximumMember2022-03-310001522860afib:BiotroniksMember2022-01-012022-03-310001522860afib:BiotroniksMember2022-03-310001522860afib:BiotroniksMember2021-12-310001522860afib:BiotroniksMember2020-12-310001522860afib:RhythmXienceMember2019-06-182019-06-180001522860afib:EarnoutConsiderationMemberafib:RhythmXienceMember2019-06-180001522860afib:EarnoutConsiderationMemberafib:RhythmXienceMemberafib:SeriesDConvertiblePreferredStocksMember2020-02-012020-02-290001522860afib:RhythmXienceMember2019-06-180001522860afib:RhythmXienceMemberafib:SeriesDConvertiblePreferredStocksMember2020-01-012020-12-310001522860afib:RhythmXienceMember2021-01-012021-12-310001522860afib:RhythmXienceMember2021-12-310001522860afib:RhythmXienceMember2022-01-012022-03-310001522860afib:RhythmXienceMember2021-01-012021-03-310001522860afib:RhythmXienceMember2022-03-310001522860us-gaap:ShortTermDebtMemberus-gaap:CorporateDebtSecuritiesMember2022-03-310001522860us-gaap:USTreasurySecuritiesMemberus-gaap:ShortTermDebtMember2022-03-310001522860us-gaap:ShortTermDebtMemberus-gaap:CommercialPaperMember2022-03-310001522860us-gaap:ShortTermDebtMemberafib:YankeeDebtSecuritiesMember2022-03-310001522860afib:SupranationalMemberus-gaap:ShortTermDebtMember2022-03-310001522860us-gaap:ShortTermDebtMemberus-gaap:AssetBackedSecuritiesMember2022-03-310001522860us-gaap:ShortTermDebtMember2022-03-310001522860us-gaap:AssetBackedSecuritiesMemberus-gaap:LongTermDebtMember2022-03-310001522860us-gaap:ShortTermDebtMemberus-gaap:CorporateDebtSecuritiesMember2021-12-310001522860us-gaap:USTreasurySecuritiesMemberus-gaap:ShortTermDebtMember2021-12-310001522860us-gaap:ShortTermDebtMemberus-gaap:CommercialPaperMember2021-12-310001522860us-gaap:ShortTermDebtMemberafib:YankeeDebtSecuritiesMember2021-12-310001522860afib:SupranationalMemberus-gaap:ShortTermDebtMember2021-12-310001522860us-gaap:ShortTermDebtMemberus-gaap:AssetBackedSecuritiesMember2021-12-310001522860us-gaap:ShortTermDebtMember2021-12-310001522860us-gaap:LongTermDebtMemberus-gaap:CorporateDebtSecuritiesMember2021-12-310001522860us-gaap:AssetBackedSecuritiesMemberus-gaap:LongTermDebtMember2021-12-310001522860us-gaap:LongTermDebtMember2021-12-310001522860us-gaap:LongTermDebtMember2022-03-310001522860us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2022-03-310001522860us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2021-12-310001522860us-gaap:OtherNoncurrentAssetsMember2022-03-310001522860us-gaap:OtherNoncurrentAssetsMember2021-12-310001522860us-gaap:EquipmentMember2022-03-310001522860us-gaap:EquipmentMember2021-12-310001522860us-gaap:FurnitureAndFixturesMember2022-03-310001522860us-gaap:FurnitureAndFixturesMember2021-12-310001522860us-gaap:OfficeEquipmentMember2022-03-310001522860us-gaap:OfficeEquipmentMember2021-12-310001522860afib:LaboratoryEquipmentAndSoftwareMember2022-03-310001522860afib:LaboratoryEquipmentAndSoftwareMember2021-12-310001522860us-gaap:LeaseholdImprovementsMember2022-03-310001522860us-gaap:LeaseholdImprovementsMember2021-12-310001522860us-gaap:ConstructionInProgressMember2022-03-310001522860us-gaap:ConstructionInProgressMember2021-12-310001522860us-gaap:DevelopedTechnologyRightsMember2022-01-012022-03-310001522860us-gaap:DevelopedTechnologyRightsMember2022-03-310001522860us-gaap:CustomerRelatedIntangibleAssetsMember2022-01-012022-03-310001522860us-gaap:CustomerRelatedIntangibleAssetsMember2022-03-310001522860us-gaap:LicensingAgreementsMember2022-01-012022-03-310001522860us-gaap:LicensingAgreementsMember2022-03-310001522860us-gaap:DevelopedTechnologyRightsMember2021-01-012021-12-310001522860us-gaap:DevelopedTechnologyRightsMember2021-12-310001522860us-gaap:CustomerRelatedIntangibleAssetsMember2021-01-012021-12-310001522860us-gaap:CustomerRelatedIntangibleAssetsMember2021-12-310001522860us-gaap:LicensingAgreementsMember2021-01-012021-12-310001522860us-gaap:LicensingAgreementsMember2021-12-310001522860afib:TwoThousandAndNineteenCreditAgreementMember2022-03-310001522860afib:TwoThousandAndNineteenCreditAgreementMember2021-12-310001522860afib:SeniorTermLoanMemberafib:TwoThousandAndNineteenCreditAgreementMember2019-05-200001522860afib:SeniorTermLoanMemberafib:TwoThousandAndNineteenCreditAgreementMember2019-05-202019-05-200001522860afib:TwoThousandAndNineteenCreditAgreementMember2019-05-200001522860afib:DefaultEventMemberafib:SeniorTermLoanMember2019-05-202019-05-200001522860afib:SeriesCConvertiblePreferredStockMemberafib:TwoThousandAndNineteenCreditAgreementMember2019-05-200001522860afib:SeriesDConvertiblePreferredStockMemberafib:TwoThousandAndNineteenCreditAgreementMember2019-05-200001522860afib:CorporateOfficeSpaceAndManufacturingFacilityMember2022-03-31utr:sqft0001522860afib:OfficeSpaceZaventemBelgiumMember2022-03-31afib:lawsuit0001522860afib:WarrantsIssuedInTwoThousandAndFifteenMemberus-gaap:CommonStockMember2022-03-310001522860afib:WarrantsIssuedInTwoThousandAndFifteenMemberus-gaap:CommonStockMember2021-12-310001522860afib:WarrantsIssuedInTwoThousandAndEighteenWithConvertibleNotesMemberus-gaap:CommonStockMember2022-03-310001522860afib:WarrantsIssuedInTwoThousandAndEighteenWithConvertibleNotesMemberus-gaap:CommonStockMember2021-12-310001522860afib:WarrantsIssuedInTwoThousandAndEighteenTermLoanMemberus-gaap:CommonStockMember2022-03-310001522860afib:WarrantsIssuedInTwoThousandAndEighteenTermLoanMemberus-gaap:CommonStockMember2021-12-310001522860afib:WarrantsIssuedInWithTwoThousandAndNineteenCreditAgreementMemberus-gaap:CommonStockMember2022-03-310001522860afib:WarrantsIssuedInWithTwoThousandAndNineteenCreditAgreementMemberus-gaap:CommonStockMember2021-12-31afib:holder00015228602021-08-012021-08-31afib:investor0001522860us-gaap:CommonStockMember2021-08-012021-08-310001522860us-gaap:SeriesAPreferredStockMember2021-08-012021-08-310001522860us-gaap:SeriesAPreferredStockMember2021-08-310001522860us-gaap:SeriesAPreferredStockMember2021-08-230001522860us-gaap:SeriesAPreferredStockMember2022-03-310001522860us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310001522860us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-03-310001522860us-gaap:RestrictedStockMember2021-01-012021-03-310001522860us-gaap:RestrictedStockMember2022-01-012022-03-310001522860afib:TwoThousandTwentyTwoInducementEquityIncentivePlanMember2022-03-310001522860afib:TwoThousandTwentyEquityIncentivePlanMember2022-03-310001522860afib:TwoThousandElevenPlanMember2022-03-310001522860afib:TwoThousandElevenPlanMember2022-01-012022-03-310001522860afib:PerformanceBasedRestrictedStockUnitsMember2019-06-012019-06-300001522860afib:PerformanceBasedRestrictedStockUnitsMember2021-12-310001522860afib:PerformanceBasedRestrictedStockUnitsMember2022-01-012022-03-310001522860afib:PerformanceBasedRestrictedStockUnitsMember2022-03-310001522860afib:TwoThousandTwentyEmployeeStockPurchasePlanMember2020-08-050001522860srt:MaximumMemberafib:TwoThousandTwentyEmployeeStockPurchasePlanMember2022-01-012022-03-310001522860us-gaap:CostOfSalesMember2022-01-012022-03-310001522860us-gaap:CostOfSalesMember2021-01-012021-03-310001522860us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-03-310001522860us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-03-310001522860us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-03-310001522860us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-03-310001522860afib:ConversionOfPreferredConvertiblesSeriesAStockMember2022-01-012022-03-310001522860afib:ConversionOfPreferredConvertiblesSeriesAStockMember2021-01-012021-03-310001522860us-gaap:EmployeeStockOptionMember2022-01-012022-03-310001522860us-gaap:EmployeeStockOptionMember2021-01-012021-03-310001522860us-gaap:WarrantMember2022-01-012022-03-310001522860us-gaap:WarrantMember2021-01-012021-03-310001522860afib:PerformanceShareUnitsAndRestrictedStockUnitsMember2022-01-012022-03-310001522860afib:PerformanceShareUnitsAndRestrictedStockUnitsMember2021-01-012021-03-310001522860afib:FourZeroOneKRetirementPlanMember2022-01-012022-03-310001522860afib:FourZeroOneKRetirementPlanMember2021-01-012021-03-310001522860afib:ConsultingAgreementMembersrt:MaximumMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberafib:DirectorAndTheChairmanMember2022-01-012022-03-310001522860afib:ConsultingAgreementMembersrt:MaximumMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberafib:DirectorAndTheChairmanMember2021-01-012021-03-310001522860afib:OrbimedRoyaltyOppurtunitiesTwoLpAndDeerfieldPrivateDesignFundLpMemberafib:TwoThousandAndNineteenCreditFacilityMember2019-12-310001522860afib:TwoThousandAndNineteenCreditFacilityMember2022-03-310001522860afib:TwoThousandAndNineteenCreditFacilityMember2021-12-310001522860afib:OrbimedRoyaltyOppurtunitiesTwoLpAndDeerfieldPrivateDesignFundLpMemberafib:TwoThousandAndNineteenCreditFacilityMember2022-01-012022-03-310001522860afib:OrbimedRoyaltyOppurtunitiesTwoLpAndDeerfieldPrivateDesignFundLpMemberafib:TwoThousandAndNineteenCreditFacilityMember2021-01-012021-03-310001522860us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberafib:LeftHeartAccessPortfolioMembersrt:ScenarioForecastMember2022-05-132023-12-310001522860us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberafib:LeftHeartAccessPortfolioMemberafib:ManufacturingQualificationRequirementsMembersrt:ScenarioForecastMember2023-12-310001522860us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMembersrt:MinimumMemberafib:RegulatoryMilestonesMemberafib:LeftHeartAccessPortfolioMembersrt:ScenarioForecastMember2023-12-310001522860us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberafib:RegulatoryMilestonesMembersrt:MaximumMemberafib:LeftHeartAccessPortfolioMembersrt:ScenarioForecastMember2023-12-310001522860us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberafib:LeftHeartAccessPortfolioMembersrt:ScenarioForecastMemberafib:DisposalGroupConsiderationProductSalesPeriodOneMember2023-12-310001522860us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberafib:LeftHeartAccessPortfolioMemberafib:DisposalGroupConsiderationProductSalesPeriodTwoMembersrt:ScenarioForecastMember2023-12-310001522860us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberafib:DisposalGroupConsiderationProductSalesPeriodThreeMemberafib:LeftHeartAccessPortfolioMembersrt:ScenarioForecastMember2023-12-310001522860afib:DisposalGroupConsiderationProductSalesPeriodFourMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberafib:LeftHeartAccessPortfolioMembersrt:ScenarioForecastMember2023-12-310001522860afib:NewDebtFacilityMemberafib:SeniorTermLoanMemberus-gaap:SubsequentEventMember2022-05-120001522860afib:NewDebtFacilityMemberafib:SeniorTermLoanMemberus-gaap:SubsequentEventMember2022-05-122022-05-120001522860afib:NewDebtFacilityMemberafib:DebtInstrumentAmortizationPaymentPeriodOneMemberafib:SeniorTermLoanMemberus-gaap:SubsequentEventMember2022-05-122022-05-120001522860afib:NewDebtFacilityMemberafib:SeniorTermLoanMemberus-gaap:SubsequentEventMemberafib:DebtInstrumentAmortizationPaymentPeriodTwoMember2022-05-122022-05-120001522860afib:NewDebtFacilityMemberafib:DebtInstrumentAmortizationPaymentPeriodThreeMemberafib:SeniorTermLoanMemberus-gaap:SubsequentEventMember2022-05-122022-05-120001522860afib:NewDebtFacilityMemberafib:SeniorTermLoanMemberus-gaap:SubsequentEventMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2022-05-122022-05-12
Washington, D.C. 20549
(Mark one)
For the quarterly period ended March 31, 2022
For the transition period from                      to                     
Commission File Number 001-39430
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
2210 Faraday Ave.,
Suite 100, Carlsbad, CA
(Address of principal executive offices)(Zip Code)
(Registrant’s telephone number, including area code) (442) 232-6080
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Name of each exchange on which registered 
Common Stock, par value $0.001 per shareAFIBThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐
Indicate by check mark whether the registrant has submitted electronically, if any, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filerAccelerated filer
Non-accelerated filerSmaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  
Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     Yes      No  ☒
Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date.
Class of Common StockOutstanding Shares as of May 9, 2022
Common Stock, $0.001 par value

Acutus Medical, Inc.
Form 10-Q
For the Quarter Ended March 31, 2022
Table of Contents

Item 1. Financial Statements.
Acutus Medical, Inc.
Condensed Consolidated Balance Sheets
March 31,
December 31,
(in thousands, except share and per share amounts)(unaudited)
Current assets:
Cash and cash equivalents$12,319 $24,071 
Marketable securities, short-term62,292 76,702 
Restricted cash150 150 
Accounts receivable2,978 3,633 
Inventory17,620 16,408 
Prepaid expenses and other current assets9,064 5,326 
Total current assets104,423 126,290 
Marketable securities, long-term4,014 7,120 
Property and equipment, net12,962 13,670 
Right-of-use assets, net4,358 4,521 
Intangible assets, net4,853 5,013 
Goodwill 12,026 
Other assets1,032 1,152 
Total assets$131,642 $169,792 
Current liabilities:
Accounts payable$4,781 $7,519 
Accrued liabilities10,632 9,096 
Contingent consideration, short-term1,400 1,500 
Operating lease liabilities, short-term501 395 
Total current liabilities17,314 18,510 
Operating lease liabilities, long-term4,471 4,591 
Long-term debt40,793 40,415 
Contingent consideration, long-term300 500 
Other long-term liabilities2 50 
Total liabilities62,880 64,066 
Commitments and contingencies (Note 12)
Stockholders' equity
Preferred stock, $0.001 par value; 5,000,000 shares authorized as of March 31, 2022 and December 31, 2021; 6,666 shares of the preferred stock, designated as Series A Common Equivalent Preferred Stock, are issued and outstanding as of March 31, 2022 and December 31, 2021
Common stock, $0.001 par value; 260,000,000 shares authorized as of March 31, 2022 and December 31, 2021; 28,279,065 and 27,957,223 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively
28 28 
Additional paid-in capital587,889 584,613 
Accumulated deficit(518,715)(478,698)
Accumulated other comprehensive loss(440)(217)
Total stockholders' equity68,762 105,726 
Total liabilities and stockholders' equity$131,642 $169,792 
The accompanying notes are an integral part of these condensed consolidated financial statements.

Acutus Medical, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
Three Months Ended March 31,
(in thousands, except share and per share amounts)(unaudited)
Revenue$3,681 $3,591 
Costs and operating expenses:
Cost of products sold6,941 6,955 
Research and development8,003 9,370 
Selling, general and administrative14,385 16,252 
Goodwill impairment12,026  
Change in fair value of contingent consideration7 (1,153)
Total costs and operating expenses42,311 31,424 
Loss from operations(38,630)(27,833)
Other income (expense):
Interest income24 40 
Interest expense(1,411)(1,388)
Total other expense, net(1,387)(1,348)
Loss before income taxes(40,017)(29,181)
Income tax benefit  
Net loss$(40,017)$(29,181)
Other comprehensive income (loss)
Unrealized (loss)/gain on marketable securities(57)6 
Foreign currency translation adjustment(166)(226)
Comprehensive loss$(40,240)$(29,401)
Net loss per common share, basic and diluted$(1.42)$(1.04)
Weighted average shares outstanding, basic and diluted28,118,090 28,031,686 
The accompanying notes are an integral part of these condensed consolidated financial statements.

Acutus Medical, Inc.
Condensed Consolidated Statements of Stockholders’ Equity
For the Three Months Ended March 31, 2022
(in thousands, except share amounts)Preferred StockCommon StockAdditional
Balance as of December 31, 20216,666 $ 27,957,223 $28 $584,613 $(478,698)$(217)$105,726 
Unrealized loss on marketable securities— — — — — — (57)(57)
Foreign currency translation adjustment— — — — — — (166)(166)
Stock option exercises — 35,478 66 — — 66 
Stock-based compensation — 192,138 — 3,028 — — 3,028 
Employee stock purchase plan shares issued — 94,226 — 182 — — 182 
Net loss— — — — — (40,017)— (40,017)
Balance as of March 31, 2022 (unaudited)6,666 $ 28,279,065 $28 $587,889 $(518,715)$(440)$68,762 

For the Three Months Ended March 31, 2021
(in thousands, except share amounts)Common StockAdditional
Income (Loss)
Balance as of December 31, 202027,991,425 $28 $487,290 $(361,015)$280 $126,583 
Unrealized gain on marketable securities— — — — 6 6 
Foreign currency translation adjustment— — — — (226)(226)
Stock option exercises27,509 — 169 — — 169 
Stock-based compensation94,231 — 2,910 — — 2,910 
Net loss— — — (29,181)— (29,181)
Balance as of March 31, 2021 (unaudited)28,113,165 $28 $490,369 $(390,196)$60 $100,261 
The accompanying notes are an integral part of these condensed consolidated financial statements.

Acutus Medical, Inc.
Condensed Consolidated Statements of Cash Flows
Three Months Ended March 31,
(in thousands)(unaudited)
Cash flows from operating activities
Net loss$(40,017)$(29,181)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense1,567 1,241 
Amortization of intangible assets160 160 
Stock-based compensation expense3,032 2,910 
Amortization of premiums on marketable securities, net173 412 
Amortization of debt issuance costs378 328 
Amortization of right-of-use assets160 180 
Goodwill impairment12,026  
Change in fair value of contingent consideration7 (1,153)
Changes in operating assets and liabilities:
Accounts receivable655 (317)
Prepaid expenses and other current assets(3,487)1,104 
Other assets120 (250)
Accounts payable(2,641)(2,091)
Accrued liabilities1,532 1,500 
Operating lease liabilities(14)(237)
Other long-term liabilities(48) 
Net cash used in operating activities(27,609)(26,273)
Cash flows from investing activities
Purchases of available-for-sale marketable securities (9,135)
Sales of available-for-sale marketable securities2,500  
Maturities of available-for-sale marketable securities14,587 25,000 
Purchases of property and equipment(1,088)(3,693)
Net cash provided by investing activities15,999 12,172 
Cash flows from financing activities
Payment of contingent consideration(290)(2,547)
Proceeds from stock options exercises66 169 
Proceeds from employee stock purchase plan182  
Net cash used in financing activities(42)(2,378)
Effect of exchange rate changes on cash, cash equivalents and restricted cash(100)(124)
Net change in cash, cash equivalents and restricted cash(11,752)(16,603)
Cash, cash equivalents and restricted cash, at the beginning of the period24,221 25,384 
Cash, cash equivalents and restricted cash, at the end of the period$12,469 $8,781 
Supplemental disclosure of cash flow information:
Cash paid for income taxes$ $35 
Cash paid for interest$1,025 $1,125 
Supplemental disclosure of noncash investing and financing activities:
Change in unrealized loss on marketable securities$57 $(6)
Change in unpaid purchases of property and equipment$(97)$(67)
Escrow release$17 $ 
The accompanying notes are an integral part of these condensed consolidated financial statements.

Acutus Medical, Inc.
Notes to Condensed Consolidated Financial Statements
Note 1—Organization and Description of Business
Acutus Medical, Inc. (the “Company”) is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. The Company designs, manufactures and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias. The Company’s product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, ablation catheters, mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. The Company was incorporated in the state of Delaware on March 25, 2011, and is located in Carlsbad, California.
Liquidity, Capital Resources and Going Concern
The Company has limited revenue, has incurred significant operating losses and negative cash flows from operations since its inception, and anticipates that it will incur significant losses for at least the next several years. As of March 31, 2022 and December 31, 2021, the Company had cash, cash equivalents and marketable securities of $78.6 million and $107.9 million, respectively. For the three months ended March 31, 2022 and 2021, net losses were $40.0 million and $29.2 million, respectively, and net cash used in operating activities was $27.6 million and $26.3 million respectively. As of March 31, 2022 and December 31, 2021, the Company had an accumulated deficit of $518.7 million and $478.7 million, respectively, and working capital of $87.1 million and $107.8 million, respectively.

Prior to the Company’s initial public offering (“IPO”) in August 2020, operations had been financed primarily by aggregate net proceeds from the sale of convertible preferred stock and principal of converted debt of $253.9 million, as well as other indebtedness. On August 10, 2020, the Company issued 10,147,058 shares of common stock in its IPO, which included 1,323,529 shares of common stock issued upon the exercise in full by the underwriters of an option to purchase additional shares of common stock, at the public offering price less underwriting discounts and commissions. The price to the public was $18.00 per share, for net proceeds of $166.3 million.

In July 2021, the Company issued 6,325,000 shares of common stock in a public offering, which included 825,000 shares of common stock issued upon the underwriter’s exercise in full of an option to purchase additional shares of common stock. The price to the public for each share was $14.00. The Company received gross proceeds of $88.6 million from the offering. Net of underwriting discounts and commission and other offering expenses, the Company received proceeds of $82.7 million from the offering.

With the closing of the Company’s IPO in August 2020, the follow on offering in July 2021 and the reduction in force ("RIF") announced in January 2022, Management believes the Company’s current cash, cash equivalents and marketable securities are sufficient to fund operations for at least the next 12 months. Under Accounting Standard Codification (“ASC”) Subtopic 205-40, Presentation of Financial Statements—Going Concern (“ASC 205-40”), the Company has the responsibility to evaluate whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date that the consolidated financial statements are issued. As required under ASC 205-40, management’s evaluation should initially not take into consideration the potential mitigating effects of management’s plans that have not been fully implemented as of the date the consolidated financial statements are issued. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern.

Substantial Doubt Raised

In performing the first step of the evaluation, the Company concluded that the following conditions raised substantial doubt about its ability to continue as a going concern:
History of net losses of $40.0 million and $29.2 million for the three months ended March 31, 2022 and 2021, respectively, and $117.7 million and $102.0 million for the years ended December 31, 2021 and December 31, 2020, respectively;
Accumulated deficit of $518.7 million and $478.7 million as of March 31, 2022 and December 31, 2021, respectively;
Disruptions in elective procedure volumes related to unanticipated impacts from COVID-19; and
History of negative gross margins.


Consideration of Management’s Plans

In performing the second step of this assessment, the Company is required to evaluate whether it is probable that its plans will be effectively implemented within one year after the consolidated financial statements are issued and whether it is probable those plans will alleviate the substantial doubt about its ability to continue as a going concern.

The Company has identified several potential actions to strengthen liquidity and optimize resources in the event actual results and other planned activities differ materially from projections. The Company is prepared to implement these actions as required by business and market conditions. These actions would improve the available cash balances, liquidity and cash flows generated from operations over the twelve-month period from the date the consolidated financial statements are issued, as follows:

Reduction in force that would be intended to extend the cash runway necessary to fund operations;
Total compensation reductions for senior executives to strengthen liquidity and to preserve key research and development, commercial and functional roles;
Increased internal identification of efficiencies within corporate functions to reduce certain external consulting and business support spend; and
Deferral and reprioritization of certain research and development programs that would involve reduced program and headcount spend.

Management Assessment of Ability to Continue as a Going Concern

The Company has a history of operating losses and negative cash flows from operations. However, despite these conditions, the Company believes management’s plans, as described more fully above, will provide sufficient liquidity to meet its financial obligations and maintain levels of liquidity as specifically required under the 2019 Credit Agreement, as defined below. Therefore, management concluded these plans alleviate the substantial doubt that was raised about the Company’s ability to continue as a going concern for at least twelve months from the date that the consolidated financial statements were issued.

Future Plans and Considerations

Although not considered for purposes of the Company’s assessment of whether substantial doubt was alleviated, the Company has retained several specialized third-party consultants and advisors to review its strategy as well as a range of options to fund the long-term growth of the Company, including non-dilutive financing, partnerships and licensing and distribution agreements.

The Company’s plans are subject to inherent risks and uncertainties, which become significantly magnified when the effects of the current pandemic and related financial crisis are included in the assessment. Accordingly, there can be no assurance that the Company’s plans can be effectively implemented and, therefore, that the conditions can be effectively mitigated.

The Company may need to raise additional funds through the issuance of debt and/or equity securities or otherwise. Until such time, if ever, that the Company can generate revenue sufficient to achieve profitability, the Company expects to finance its operations through equity or debt financings, which may not be available to the Company on the timing needed or on terms that the Company deems to be favorable. To the extent that the Company raises additional capital through the sale of equity or convertible debt securities, the ownership interest of its stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting the Company’s ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. If the Company is unable to maintain sufficient financial resources, its business, financial condition and results of operations will be materially and adversely affected. The Company may be required to delay, limit, reduce or terminate its product discovery and development activities or future commercialization efforts.

Impact of COVID-19

Beginning in March 2020, the COVID-19 pandemic and the measures imposed to contain this pandemic disrupted and are expected to continue to impact the Company's business. For example, on March 19, 2020, the Executive Department of the State of California issued Executive Order N-33-20, ordering all individuals in the State of California to stay home or at their place of residence except as needed to maintain continuity of operations of the federal critical infrastructure sectors. The Company's primary operations are located in Carlsbad, California. As a result of such order, the majority of the Company’s employees have telecommuted, which may impact certain of its operations over the near term and long term. Moreover, beginning in March 2020 and continuing through the filing of this Form 10-Q, access to hospitals and other customer sites was

restricted to essential personnel, which negatively impacted the Company’s ability to install its AcQMap consoles and workstations in new accounts and for sales representatives and mappers to promote the use of the Company’s products with physicians. Moreover, hospitals and other therapeutic centers suspended many elective procedures, resulting in a significantly reduced volume of procedures using the Company's products. In addition, all clinical trials in Europe were suspended with follow-ups for clinical trials done via telecom, and the Company believes enrollment timing in its planned clinical trials will be slowed due to COVID-19 driven delayed access to enrollment sites. As a result of the interruptions to the business due to COVID-19, the Company enacted a cash conservation program, which included delaying certain non-critical capital expenditures and other projects and implementing a hiring freeze, headcount reductions and temporary compensation reductions (through August 2020). The effects of the pandemic began to decrease in late April 2020 as electrophysiology labs began reopening and procedure volumes began increasing as compared to COVID-19 related low points in March 2020. The Company’s IPO in August 2020 provided resources sufficient to restore compensation reductions to pre-COVID levels, as well as to restart hiring and capital expenditures in support of its growth.

Over the past 24-months, the Company has continued to observe intermittent suspension of many elective procedures associated with the resurgence of COVID-19 in geographies where it sells, markets and distributes its products. In addition, the impact of COVID-19 has varied by region and by healthcare facility, which has hampered the Company’s ability to forecast the sustained impact on its business from COVID-19. The Company continues to see intermittent suspension of many elective procedures in many hospitals, resulting in reduced volume of procedures using its products. In addition, the Company has experienced personnel and other resource shortages at hospitals at which procedures using its products otherwise could be used; disruptions or restrictions on the ability of many of its employees and of third parties on which it relies to work effectively, including because of adherence to governmental orders or recommendations or to internal policies intended to reduce the spread of COVID-19; and temporary closures of its facilities and of the facilities of its customers and suppliers. The magnitude of the impact of the COVID-19 pandemic on productivity, results of operations and financial position, and its disruption to the Company’s business and clinical programs and timelines, will depend, in part, on the length and severity of the pandemic, associated restrictions and other measures designed to prevent the spread of COVID-19 and on the Company’s ability to conduct business in the ordinary course. Quarantines, shelter-in-place, vaccine mandates and similar government orders have also impacted, and may continue to impact, the Company’s third-party manufacturers and suppliers, and could in turn adversely impact the availability or cost of materials, which could disrupt the Company’s supply chain. The markets the Company serves are likely to see continued impacts from COVID-19 for the foreseeable future, and the emergence of new variants of COVID-19 creates significant uncertainty as to how long COVID-19 will continue to impact the Company’s business.
Note 2—Summary of Significant Accounting Policies
Basis of Presentation
The condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and note disclosures normally included in the Company’s annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These condensed consolidated financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period.
Principles of Consolidation
The condensed consolidated financial statements include the accounts of Acutus Medical, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates and Assumptions
The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and disclosures of contingent assets and liabilities. The most significant estimates and assumptions in the Company’s condensed consolidated financial statements include, but are not limited to, revenue recognition, useful lives of intangible assets, assessment of impairment of goodwill, measurement of operating lease liabilities, and the fair value of common stock, stock options, warrants, intangible assets and contingent consideration. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making

judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results could differ from those estimates.
Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one operating segment.
Cash and Cash Equivalents and Restricted Cash
The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. All of the Company’s cash equivalents have liquid markets and high credit ratings. The Company maintains its cash in bank deposits and other accounts, the balances of which, at times and as of March 31, 2022 and December 31, 2021, exceeded federally insured limits.
Restricted cash serves as collateral for the Company’s corporate credit card program. The following table reconciles cash, cash equivalents and restricted cash in the condensed consolidated balance sheets to the total shown on the condensed consolidated statement of cash flows (in thousands):
March 31,
December 31,
Cash and cash equivalents$12,319 $24,071 
Restricted cash150 150 
Total cash, cash equivalents and restricted cash$12,469 $24,221 
Marketable Securities
The Company considers its debt securities to be available-for-sale securities. Available-for-sale securities are classified as cash equivalents or short-term or long-term marketable securities based on the maturity date at time of purchase and their availability to meet current operating requirements. Marketable securities that mature in three months or less from the date of purchase are classified as cash equivalents. Marketable securities, excluding cash equivalents, that mature in one year or less are classified as short-term available-for-sale securities and are reported as a component of current assets.
Securities that are classified as available-for-sale are measured at fair value with temporary unrealized gains and losses reported in other comprehensive loss, and as a component of stockholders’ equity until their disposition or maturity. See “Fair Value Measurements” below. The Company reviews all available-for-sale securities at each period end to determine if they remain available-for-sale based on the Company’s current intent and ability to sell the security if it is required to do so. Realized gains and losses from the sale of marketable securities, if any, are calculated using the specific-identification method.
Marketable securities are subject to a periodic impairment review. The Company may recognize an impairment charge when a decline in the fair value of investments below the cost basis is determined to be other-than-temporary. In determining whether a decline in market value is other-than-temporary, various factors are considered, including the cause, duration of time and severity of the impairment, any adverse changes in the investees’ financial condition and the Company’s intent and ability to hold the security for a period of time sufficient to allow for an anticipated recovery in market value. Declines in value judged to be other-than-temporary are included in the Company’s condensed consolidated statements of operations and comprehensive loss. The Company did not record any other-than-temporary impairments related to marketable securities in the Company’s condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2022 and 2021.
Concentrations of Credit Risk and Off-Balance Sheet Risk
Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents, restricted cash, accounts receivable and marketable securities. Cash and restricted cash are maintained in accounts with financial institutions which, at times, may exceed the Federal depository insurance coverage of $0.25 million. The Company has not experienced losses on these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is not significant. The Company’s marketable securities portfolio primarily consists of

investments in commercial paper, Yankee debt securities, supranational, U.S. treasury securities, asset-backed securities and short-term high credit quality corporate debt securities.
Revenue from Contracts with Customers
The Company accounts for revenue earned from contracts with customers under ASC 606, Revenue from Contracts with Customers (“ASC 606”), and ASC 842, Leases ("ASC 842"). The core principle of ASC 606 is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle:
Step 1: Identify the contract with the customer.
Step 2: Identify the performance obligations in the contract.
Step 3: Determine the transaction price.
Step 4: Allocate the transaction price to the performance obligations in the contract.
Step 5: Recognize revenue when, or as, the company satisfies a performance obligation.

ASC 842 provides guidance on determining if an agreement contains a lease. ASC 842 defines a lease as a contract, or part of a contract, that conveys the right to control the use of identified property, plant or equipment for a period of time in exchange for consideration.

For new customers, the Company places its medical diagnostic equipment, AcQMap System, at customer sites under evaluation agreements and generates revenue from the sale of disposable products used with the AcQMap System. Disposable products primarily include AcQMap Catheters and AcQGuide Steerable Sheaths. Outside of the U.S., the Company also has a Qubic Force Device which generates revenue from the sale of the AcQBlate FORCE ablation catheters. The Company provides the disposable products in exchange for consideration, which occurs when a customer submits a purchase order and the Company provides disposables at the agreed upon prices in the invoice. Generally, customers purchase disposable products using separate purchase orders after the equipment has been provided to the customer for free with no binding agreement or requirement to purchase any disposable products. The Company has elected the practical expedient and accounting policy election to account for the shipping and handling as activities to fulfill the promise to transfer the disposable products and not as a separate performance obligation.

The Company sells the AcQMap System to customers along with software updates on a when-and-if-available basis, as well as the Qubic Force Device and a transseptal crossing line of products which can be used in a variety of heart procedures and does not need to be accompanied with an AcQMap System or Qubic Force Device. Included in the transseptal crossing line of products are primarily the AcQRef introducer sheath, the AcQGuide sheaths and the AcQCross Transseptal Dilator/Needle.

The Company also enters into deferred equipment agreements that are generally structured such that the Company agrees to provide an AcQMap System at no up-front charge, with title of the device transferring to the customer at the end of the contract term, in exchange for the customer’s commitment to purchase disposables at a specified price over the term of the agreement, which generally ranges from two to four years. The Company determined that the deferred equipment agreements include embedded sales-type leases. The Company allocates contract consideration under deferred equipment agreements containing fixed annual disposable purchase commitments to the underlying lease and non-lease components at contract inception. The Company expenses the cost of the device at the inception of the agreement and records a financial lease asset equal to the gross consideration allocated to the lease. The lease asset will be reduced by payments for minimum disposable purchases that are allocated to the lease.

Lastly, the Company enters into short-term operating leases, for the rental of the system after an evaluation. These lease agreements impose no requirement on the customer to purchase the equipment and the equipment is not transferred to the customer at the end of the lease term. The short-term nature of the lease agreements does not result in lease payments accumulating to an amount that equals the value of the equipment nor is the lease term reflective of the economic life of the equipment.
The Company’s contracts primarily include fixed consideration. Generally, there are no discounts, rebates, returns or other forms of variable consideration. Customers are generally required to pay within 30 to 60 days.
The delivery of disposable products are performance obligations satisfied at a point in time. The disposable products are shipped Free on Board (“FOB”) shipping point or FOB destination. For disposable products that are shipped FOB shipping point, the customer has the significant risks and rewards of ownership and legal title to the assets when the disposable products leave the Company’s shipping facilities, thus the customer obtains control and revenue is recognized at that point in time. Revenue is recognized on delivery for disposable products shipped via FOB destination.

For direct customers, the installation and delivery of the AcQMap System is satisfied at a point in time when the installation is complete, which is when the customer can benefit and has control of the system. For AcQMap System sales sold to Biotronik SE & Co. KG (“Biotronik”), the installation is not a performance obligation as it is performed by Biotronik, and therefore the AcQMap System is satisfied at a point in time when they have control of the system. The Company’s software updates and equipment service performance obligations are satisfied evenly over time as the customer simultaneously receives and consumes the benefits of the Company’s performance for these services throughout the service period.
The Company allocates the transaction price to each performance obligation identified in the contract based on the relative standalone selling price (“SSP”). The Company determines SSP for the purposes of allocating the transaction price to each performance obligation based on the adjusted market assessment approach that maximizes the use of observable inputs, which includes, but is not limited to, transactions where the specific performance obligations are sold separately, list prices and offers to customers.
Except for the deferred equipment agreements noted above, the Company’s contracts with customers generally have an expected duration of one year or less, and therefore the Company has elected the practical expedient in ASC 606 to not disclose information about its remaining performance obligations. Any incremental costs to obtain contracts are recorded as selling, general and administrative expense as incurred due to the short duration of the Company’s contracts. The Company’s contract balances consisted solely of accounts receivable as of March 31, 2022 and December 31, 2021.
In May 2020, the Company entered into bi-lateral distribution agreements with Biotronik (the “Bi-Lateral Distribution Agreements”). Pursuant to the Bi-Lateral Distribution Agreements, the Company obtained a non-exclusive license to distribute a range of Biotronik’s products and accessories in the United States, Canada, China, Hong Kong and multiple Western European countries under the Company’s private label. Moreover, if an investigational device exemption (“IDE”) clinical trial is required for these products to obtain regulatory approval in the United States, or a clinical trial is required for these products to obtain regulatory approval in China, the Company will obtain an exclusive distribution right in such territories for a term of up to five years commencing on the date of regulatory approval if the Company covers the cost of the IDE or other clinical trial and the Company conducts such study within a specified period. Biotronik also agreed to distribute the Company’s products and accessories in Germany, Japan, Mexico, Switzerland and multiple countries in Asia-Pacific, Eastern Europe, the Middle East and South America. The Company also granted Biotronik a co-exclusive right to distribute these products in Hong Kong. Each party will pay to the other party specified transfer prices on the sale of the other party’s products and, accordingly, will earn a distribution margin on the sale of the other party’s products.
The following table sets forth the Company’s revenue for disposables, systems and service/other for the three months ended March 31, 2022 and 2021 (in thousands):
Three Months Ended March 31,
Disposables$3,211 $2,342 
Systems 969 
Service/Other470 280 
Total revenue$3,681 $3,591 
The following table provides revenue by geographic location for the three months ended March 31, 2022 and 2021 (in thousands):
Three Months Ended March 31,
United States$2,023 $1,581 
Outside the United States1,658 2,010 
Total revenue$3,681 $3,591 

Inventory is comprised of raw materials, direct labor and manufacturing overhead and is stated at the lower of cost (first-in, first-out basis) or net realizable value. The Company recorded write-downs for excess and obsolete inventory based on management’s review of inventories on hand, compared to estimated future usage and sales, shelf-life and assumptions about the likelihood of obsolescence of $1.0 million and $0.1 million for the three months ended March 31, 2022 and 2021, respectively.
Accounts Receivable
The Company evaluates the collectability of its accounts receivable based on various factors including historical experience, the length of time the receivables are past due and the financial health of the customer. The Company reserves specific receivables if collectability is no longer reasonably assured. Based upon the assessment of these factors, the Company did not record an allowance for uncollectible accounts as of March 31, 2022 and December 31, 2021.
Property and Equipment, Net
Property and equipment are recorded at cost. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets, generally three to five years, or, in the case of leasehold improvements, over the lesser of the useful life of the related asset or the lease term.
Intangible Assets
Intangible assets consist of acquired developed technology, acquired in-process technology, trademarks and trade names and a customer-related intangible which were acquired as part of the acquisition of Rhythm Xience, Inc. (“Rhythm Xience”) in June 2019. The Company’s intangible assets also include a license agreement with Biotronik. The Company determines the appropriate useful life of its finite-lived intangible assets by performing an analysis of expected cash flows of the acquired assets. Finite-lived intangible assets are amortized over their estimated useful lives using the straight-line method, which approximates the pattern in which the economic benefits are consumed. Acquired in-process technology was classified as an indefinite-lived intangible asset, until the receipt of Food and Drug Administration (the “FDA”) approval for the technology in January 2020. Once the FDA approval was received, the in-process technology was classified as a finite-lived intangible and amortization for in-process technology began. Indefinite-lived intangible assets are tested for impairment at least annually and are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Indefinite-lived intangible assets are impaired if their estimated fair values are less than their carrying value.
Goodwill represents the excess of the purchase price of an entity over the estimated fair value of the assets acquired and liabilities assumed, and it is presented as goodwill in the accompanying condensed consolidated balance sheets. Under ASC 350, Intangibles – Goodwill and Other (“ASC 350”), goodwill is not amortized but is subject to periodic impairment testing. ASC 350 requires that an entity assign its goodwill to reporting units and test each reporting unit’s goodwill for impairment at least on an annual basis and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. In the evaluation of goodwill for impairment, which is performed annually during the fourth quarter, the Company first assesses qualitative factors to determine whether the existence of events or circumstances led to a determination that it was more likely than not that the fair value of a reporting unit is less than its carrying amount. If, after assessing the totality of events or circumstances, it is determined that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company is required to perform the quantitative goodwill impairment test. The Company has one reporting unit. For the three months ended March 31, 2022, the Company fully impaired its goodwill balance of $12.0 million. Refer to Note 8 - Goodwill and Intangible Assets for further details.
Impairment of Long-Lived Assets
The Company reviews long-lived assets, including property and equipment and finite-lived intangible assets, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. An impairment loss is recognized when the asset’s carrying value exceeds the total undiscounted cash flows expected from its use and eventual disposition. The amount of the impairment loss is determined as the excess of the carrying value of the asset over its fair value. For the three months ended March 31, 2022 and 2021, the Company determined that there was no impairment of property and equipment or intangible assets.

Foreign Currency Translation and Transactions
The assets, liabilities and results of operations of Acutus Medical N.V. and Acutus Medical UK Limited are measured using their functional currency, the Euro and British Pound Sterling, respectively, which is the currency of the primary foreign economic environment in which the subsidiaries operate. Upon consolidating these entities with the Company, their assets and liabilities are translated to U.S. dollars at currency exchange rates as of the balance sheet date and their revenues and expenses are translated at the weighted average currency exchange rates during the applicable reporting periods. Translation adjustments resulting from the process of translating the entities’ financial statements are reported in accumulated other comprehensive loss in the condensed consolidated balance sheets and foreign currency translation adjustment in the condensed consolidated statements of operations and comprehensive loss.
Lessee Leases
The Company accounts for its lessee leases under ASC 842. Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases, and are recorded on the condensed consolidated balance sheet as both a right-of-use asset and a lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset results in straight-line rent expense over the lease term. Variable lease expenses are recorded when incurred.
In calculating the right-of-use asset and lease liability, the Company elects to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the guidance as an accounting policy election.
Cost of Products Sold
Cost of products sold includes raw materials, direct labor, manufacturing overhead, shipping and receiving costs and other less significant indirect costs related to the production of the Company’s products.
Research and Development
The Company is actively engaged in new product research and development efforts. Research and development expenses consist primarily of salaries and employee-related costs (including stock-based compensation) for personnel directly engaged in research and development activities, clinical trial expenses, equipment costs, material costs, allocated rent and facilities costs and depreciation.
In April 2021, the Company and Biotronik entered into a Feasibility and Development Agreement to pursue the development of hardware, software and IT infrastructure to implement the Qubic Connect System ("QBS"). The QBS will allow data transfer from multiple diagnostic and therapeutic medical products during an electrophysiology procedure to be aggregated and analyzed for the purposes of designing improved treatment protocols.
Research and development expenses relating to possible future products are expensed as incurred. The Company also accrues and expenses costs for activities associated with clinical trials performed by third parties as incurred. All other costs relative to setting up clinical trial sites are expensed as incurred. Clinical trial site costs related to patient enrollment are accrued as patients are entered into the trials.
Selling, General and Administrative
Selling, general and administrative (“SG&A”) expenses consist primarily of salaries and employee-related costs (including stock-based compensation) for personnel in sales, executive, finance and other administrative functions, allocated rent and facilities costs, legal fees relating to intellectual property and corporate matters, professional fees for accounting and consulting services, marketing costs and insurance costs. The Company expenses all SG&A costs as incurred.
Restructuring expense consists of severance expenses related to employees affected by the organizational RIF. The RIF was made to align resources with the Company's current strategic direction.
Employee Retention Credit

The Coronavirus Aid, Relief and Economic Security (“CARES”) Act provides an employee retention credit (“CARES Employee Retention Credit”), which is a refundable tax credit against certain employment taxes of up to $5 thousand per employee for eligible employers. The tax credit is equal to 50% of qualified wages paid to employees during a quarter, capped at $10 thousand of qualified wages per employee per calendar year through December 31, 2020. Additional relief provisions were passed by the United States government, which extended and expanded the qualified wage caps on these credits through September 30, 2021. Based on these additional provisions, the tax credit is now equal to 70% of qualified wages paid to employees during a quarter beginning with the first quarter of 2021, and the limit on qualified wages per employee has been increased to $10 thousand of qualified wages per quarter instead of per calendar year.

The Company qualifies for the tax credit under the CARES Act. The Company filed 2021 Form 941-X Adjusted Employer’s Quarterly Federal Tax Return or Claim for Refund for the quarters ended March 31, 2021 and June 30, 2021 on March 24, 2022. The refunds due are an aggregate of $4.0 million for the quarters ended March 31, 2021 and June 30, 2021. The Company filed its 2020 Form 941-X Adjusted Employer’s Quarterly Federal Tax Return or Claim for Refund for the period March 12, 2020 through December 31, 2020 on March 31, 2022. The refunds due for that period are an aggregate of $0.6 million.

The Company elected to classify the ERC amounts as a reduction to payroll tax expense. During the three months ended March 31, 2022, the Company recorded $1.5 million, $1.4 million and $1.7 million related to the CARES Employee Retention Credit within cost of products sold, research and development expense and SG&A expense, respectively, on the Company’s condensed consolidated statement of operations and comprehensive loss. As of March 31, 2022, the Company has a $4.6 million receivable balance from the United States government related to the CARES Act, which is recorded in “Prepaid expenses and other current assets” on the Company’s condensed consolidated balance sheet.
Fair Value Measurements
Fair value measurements are based on the premise that fair value is an exit price representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the following three-tier fair value hierarchy has been used in determining the inputs used in measuring fair value:
Level 1—Quoted prices in active markets for identical assets or liabilities.
Level 2—Observable inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.
Level 3—Unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.
Financial instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Management’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. The use of different assumptions and/or estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed or initial amounts recorded may not be indicative of the amount that the Company or holders of the instruments could realize in a current market exchange. There were no transfers made among the three levels in the fair value hierarchy for the three months ended March 31, 2022 and 2021.
As of March 31, 2022 and December 31, 2021, the Company’s cash (excluding cash equivalents which are recorded at fair value on a recurring basis), restricted cash, accounts receivable, accounts payable and accrued expenses were carried at cost, which approximates the fair values due to the short-term nature of the instruments.
The carrying amount of the Company’s long-term debt approximates fair value due to its variable market interest rate and management’s opinion that current rates and terms that would be available to the Company with the same maturity and security structure would be essentially equivalent to that of the Company’s long-term debt.
The following tables classify the Company’s financial assets and liabilities measured at fair value on a recurring basis into the fair value hierarchy as of March 31, 2022 and December 31, 2021 (in thousands):

Fair Value Measurements as of March 31, 2022
in Active
Markets for
(Level 1)
(Level 2)
(Level 3)
Fair Value at
March 31,
Assets included in:
Cash and cash equivalents
Money market securities$10,376 $ $ $10,376 
Marketable securities at fair value
Corporate debt securities 4,046  4,046 
U.S. treasury securities 5,042  5,042 
Commercial paper 36,775  36,775 
Yankee debt securities 3,877  3,877 
Supranational 3,019  3,019 
Asset-backed securities 13,547  13,547 
Total fair value$10,376 $66,306 $ $76,682 
Liabilities included in:
Contingent consideration$ $ $1,700 $1,700 
Total fair value$ $ $1,700 $1,700 
Fair Value Measurements as of December 31, 2021
in Active
Markets for
(Level 1)
(Level 2)
(Level 3)
Fair Value at
December 31,
Assets included in:
Cash and cash equivalents
Money market securities$21,893 $ $ $21,893 
Marketable securities at fair value
Corporate debt securities 18,860  18,860 
U.S. treasury securities 5,064  5,064 
Commercial paper 36,759  36,759 
Yankee debt securities 3,932  3,932 
Supranational 3,051  3,051 
Asset-backed securities 16,156  16,156 
Total fair value$21,893 $83,822 $ $105,715 
Liabilities included in:
Contingent consideration$ $ $2,000 $2,000 
Total fair value$ $ $2,000 $2,000 
The fair value of the Company’s money market securities is determined using quoted market prices in active markets for identical assets.

The Company’s portfolio of marketable securities is comprised of commercial paper, asset-backed securities, U.S. treasury securities, Yankee debt securities, supranational and short-term highly liquid, high credit quality corporate debt securities. The fair value for the available-for-sale marketable securities is determined based on trade prices in active markets for identical assets (Level 1 inputs) or valuation models using inputs that are observable either directly or indirectly (Level 2 inputs), such as quoted prices for similar assets, yield curve, volatility factors, credit spreads, default rates, loss severity, current market and contractual prices for the underlying instruments, broker and dealer quotes, as well as other relevant economic measures.
The following table presents changes in Level 3 liabilities measured at fair value for the three months ended March 31, 2022 (in thousands):
Balance, December 31, 2021$2,000 
Payment of contingent consideration(290)
Escrow release(1)
Change in fair value7 
Balance, March 31, 2022 (unaudited)$1,700 
(1) As part of the Rhythm Xience acquisition (see Note 3), the first $0.5 million earned related to revenue success payments was paid at the end of the first month following the end of the quarter in which the revenue success payments were earned, into an escrow account until the expiration of an additional 18 month hold-back period commencing with the end of the quarter during which such revenue success payment amounts were earned. Amounts noted above were released from the escrow account.
Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long-dated volatilities) inputs.

The fair value of the contingent consideration from the acquisition of Rhythm Xience (see Note 3) represents the estimated fair value of future payments due to the sellers of Rhythm Xience based on the achievement of certain milestones and revenue-based targets in certain years. The initial fair value of the revenue-based contingent consideration was calculated through the use of a Monte Carlo simulation using revenue projections for the respective earn-out period, corresponding targets and approximate timing of payments as outlined in the purchase agreement. The analyses used the following assumptions: (i) expected term; (ii) risk-adjusted net sales; (iii) risk-free interest rate and (iv) expected volatility of net sales. Estimated payments, as determined through the respective model, were further discounted by a credit spread assumption to account for credit risk. The fair value of the milestones-based contingent consideration was determined by probability weighting and discounting to the respective valuation date at the Company’s cost of debt. The Company’s cost of debt was determined by performing a synthetic credit rating for the Company and selecting yields based on companies with a similar credit rating. The contingent consideration is revalued to fair value each period, and any increase or decrease is recorded in operating loss. The fair value of the contingent consideration may be impacted by certain unobservable inputs, most significantly with regard to projected performance, expected term, discount rates, expected volatility and historical performance. Significant changes to these inputs in isolation, including how these inputs are weighted, could result in a significantly different fair value measurement. The weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring the contingent consideration from the acquisition of Rhythm Xience as of March 31, 2022 and December 31, 2021 were as follows:
March 31, 2022December 31, 2021
Risk-free interest rate2.00%0.60%
Expected term in years
1.0 - 2.0
1.0 - 2.0
Expected volatility25.1%28.8%
Stock-Based Compensation
The Company accounts for all stock-based payments to employees and non-employees, including grants of stock options, restricted stock awards (“RSAs”), restricted stock units (“RSUs”) and restricted stock units with non-market performance and service conditions (“PSUs”) to be recognized in the condensed consolidated financial statements, based on their respective grant date fair values. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. The RSAs, RSUs and PSUs are valued based on the fair value of the Company’s common stock on the date of grant. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. The Company expenses stock-based compensation

related to stock options, RSAs and RSUs over the requisite service period. As the PSUs have a performance condition, compensation expense was recognized for each vesting tranche over the respective requisite service period of each tranche upon the registration statement becoming effective on August 5, 2020, when the Company’s management deemed it probable that the performance conditions were satisfied. The Company recognized a cumulative true-up adjustment related to PSUs once the conditions became probable of being satisfied as the related service period had been completed in a prior period. All stock-based compensation costs are recorded in cost of products sold, research and development expense or SG&A expense in the condensed consolidated statements of operations and comprehensive loss based upon the respective employee’s or non-employee’s roles within the Company. Forfeitures are recorded as they occur. See also “Note 15—Stock-Based Compensation” below.
Income Taxes
Income taxes are recorded in accordance with ASC 740, Income Taxes (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse, and net operating loss (“NOL”) carryforwards and research and development tax credit carryforwards. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.

The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.
Business Combinations
The Company accounts for business acquisitions using the acquisition method of accounting based on ASC 805, Business Combinations (“ASC 805”), which requires recognition and measurement of all identifiable assets acquired and liabilities assumed at their fair value as of the date control is obtained. The Company determines the fair value of assets acquired and liabilities assumed based upon its best estimates of the acquisition-date fair value of assets acquired and liabilities assumed in the acquisition. Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired. Subsequent adjustments to fair value of any contingent consideration are recorded to the Company’s condensed consolidated statements of operations and comprehensive loss.
Recently Adopted Accounting Pronouncements
In May 2021, the FASB issued ASU No. 2021-05, Leases (Topic 842), Lessors – Certain Leases with Variable Lease Payments, which clarifies that lessors should classify and account for a lease with variable lease payments that do not depend on a reference index or a rate as an operating lease. This ASU is effective for smaller reporting companies in 2022. The Company adopted this guidance in the first quarter of 2022, which did not have a material impact on its condensed consolidated financial statements.
In April 2021, the FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt Modifications and Extinguishments (Subtopic 470-50), Compensation Stock Compensation (Topic 718), and Derivatives and Hedging Contracts in Entity’s Own Equity (Subtopic 815-40), which provides clarification on how to account for a modification or exchange of free-standing equity-classified written call options that remain equity classified after the modification or exchange. This ASU is effective for smaller reporting companies in 2022. The Company adopted this guidance in the first quarter of 2022, which did not have a material impact on its condensed consolidated financial statements.
Accounting Pronouncements to Be Adopted
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326). The ASU sets forth a “current expected credit loss” model which requires the Company to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions and reasonable supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost, available-for-sale debt securities and applies to certain off-balance sheet credit exposures. This ASU is effective for

smaller reporting companies in 2023. The Company is currently assessing the impact of the adoption of this ASU on its condensed consolidated financial statements.
In March 2020, the FASB issued ASU No. 2020-4, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting, which provides temporary optional guidance to ease the potential burden in accounting for reference rate reform. The new guidance provides optional expedients and exceptions for applying U.S. GAAP to transactions affected by reference rate reform if certain criteria are met. These transactions include contract modifications, hedging relationships and sale or transfer of debt securities classified as held-to-maturity. Entities may apply the provisions of the new standard as of the beginning of the reporting period when the election is made (i.e., as early as the first quarter of 2020). Unlike other topics, the provisions of this update are only available until December 31, 2022, when the reference rate replacement activity is expected to have been completed. The Company is currently evaluating the impact of this standard on its condensed consolidated financial statements and has yet to elect an adoption date.
Note 3—Asset Acquisition and Business Combination
Biotronik Asset Acquisition
In July 2019, the Company entered into a License and Distribution Agreement with Biotronik and VascoMed GmbH (the “Biotronik Parties”) to obtain certain licenses to the Biotronik Parties’ patents, whereby the Company acquired certain manufacturing equipment and obtained from the Biotronik Parties a license under certain patents and technology to develop, commercialize, distribute and manufacture the AcQBlate FORCE ablation catheters and Qubic Force Device (the “Biotronik
Asset Acquisition"). In exchange for the rights granted to the Company, the Company made cash payments totaling $10.0 million during the year ended December 31, 2020 and issued 273,070 shares of Series D convertible preferred stock valued at $5.0 million during the three months ended March 31, 2020. The implied value of $5.0 million was recorded as an accrued liability as of December 31, 2019. In accordance with ASC 805, the Biotronik Asset Acquisition was accounted for as an asset acquisition as substantially all of the $15.0 million value transferred to Biotronik was allocated to intellectual property. On the acquisition date, the products licensed had not yet received regulatory approval and the intellectual property did not have an alternative use. Accordingly, the $15.0 million paid to Biotronik was immediately charged to research and development expense—license acquired in the condensed consolidated statement of operations and comprehensive loss in July 2019.
Additional contingent milestone payments of up to $10.0 million, of which $2.0 million has been paid as of March 31, 2022, are to be made to the Biotronik Parties contingent upon certain regulatory approvals and first commercial sale. In further consideration of the rights granted, beginning with the Company’s first commercial sale of the first force sensing ablation catheter within the licensed product line, the Company also makes per unit royalty payments. As of March 31, 2022, less than $0.1 million has been included within accrued liabilities for these royalties. The Company determined that the remaining $8.0 million contingent milestones are not probable and estimable and therefore have not been recorded as a liability as of March 31, 2022 and December 31, 2021. Upon regulatory approval in December 2020 of the Company’s force sensing ablation catheter in Europe, the $2.0 million milestone was capitalized and is being amortized, and the royalty payments are recorded as cost of products sold as sales of catheters are recognized.
Rhythm Xience Business Combination
On June 18, 2019 (the “Acquisition Date”), the Company acquired an integrated family of transseptal crossing and steerable introducer systems through its acquisition of Rhythm Xience for $3.0 million in cash in exchange for all of the stock of Rhythm Xience (the “Rhythm Xience Acquisition”). The cash payment did not include the potential $17.0 million in earn out consideration, of which $2.2 million was paid with the issuance of Series D convertible preferred stock in February 2020 and the remainder is to be paid based on the achievement of certain regulatory milestones and revenue milestones. In accordance with ASC 805, the Rhythm Xience Acquisition was accounted for as a business combination.
As part of the Rhythm Xience Acquisition, the Company recorded a contingent consideration liability for potential additional payments due to the sellers of Rhythm Xience if certain regulatory approval milestones and revenue milestones are achieved. The initial contingent consideration liability of $13.4 million was based on the fair value of the contingent consideration liability at the Acquisition Date. During the year ended December 31, 2020, the Company issued 119,993 shares of Series D convertible preferred stock and paid $2.5 million of the contingent consideration for the achievement of certain regulatory and revenue milestones. During the year ended December 31, 2021, the Company paid an additional $3.4 million of the contingent consideration for the achievement of certain regulatory and revenue milestones. During the three months ended March 31, 2022, the Company paid an additional $0.3 million of the contingent consideration for the achievement of certain revenue milestones. Additionally, the Company recorded less than a $0.1 million increase and a $1.2 million decrease to the fair value of the contingent consideration liability for the three months ended March 31, 2022 and 2021, respectively, which is included in change in fair value of contingent consideration in the condensed consolidated statements of operations and comprehensive

loss. As of March 31, 2022, the contingent consideration liability of $1.7 million is the fair value of the remaining payments due to the sellers of Rhythm Xience if certain revenue milestones are achieved.
Note 4—Marketable Securities
Marketable securities consisted of the following as of March 31, 2022 and December 31, 2021 (in thousands):
March 31, 2022 (unaudited)
Fair Value
Available-for-sale securities - short-term:
Corporate debt securities$4,046 $ $ $4,046 
U.S. treasury securities5,076  (34)5,042 
Commercial paper36,775   36,775 
Yankee debt securities3,897  (20)3,877 
Supranational3,027  (8)3,019 
Asset-backed securities, short-term9,565  (32)9,533 
Total available-for-sale securities - short-term62,386  (94)62,292 
Asset-backed securities, long term4,022  (8)4,014 
Total available-for-sale securities$66,408 $ $(102)$66,306 
December 31, 2021
Fair Value
Available-for-sale securities - short-term:
Corporate debt securities, short-term$15,786 $ $(6)$15,780 
U.S. treasury securities5,073  (9)5,064 
Commercial paper36,759 $  36,759 
Yankee debt securities3,941  (9)3,932 
Supranational3,054  (3)3,051 
Asset-backed securities, short-term12,128  (12)12,116 
Total available-for-sale securities - short-term76,741  (39)76,702 
Corporate debt securities, long-term3,082  (2)3,080 
Asset-backed securities, long-term4,044  (4)4,040 
Total available-for-sale securities - long-term7,126  (6)7,120 
Total available-for-sale securities$83,867 $ $(45)$83,822 
As of March 31, 2022, the Company’s available-for-sale securities classified as short-term of $62.3 million mature in one year or less and the available-for-sale securities classified as long-term of $4.0 million mature within four years. As of December 31, 2021, the Company’s available-for-sale securities classified as short-term of $76.7 million mature in one year or less and the available-for-sale securities classified as long-term of $7.1 million mature within two years.

Note 5—Inventory
Inventory as of March 31, 2022 and December 31, 2021 consisted of the following (in thousands):
March 31,
December 31,
Raw materials$7,898 $6,779 
Work in process2,181 1,772 
Finished goods7,541 7,857 
Total inventory$17,620 $16,408 
Note 6—Lessor Sales-Type Leases
The Company recognizes revenue and costs, as well as a lease receivable, at the time embedded sales-type leases within its deferred equipment agreements commence. There was no lease revenue related to sales-type leases for the three months ended March 31, 2022. There was $0.9 million lease revenue related to sales-type leases for the three months ended March 31, 2021, and is included within revenue in the accompanying condensed consolidated statements of operations and comprehensive loss. Costs related to embedded leases within the Company’s deferred equipment agreements are included in cost of products sold in the accompanying condensed consolidated statements of operations and comprehensive loss.
The Company has a short-term lease receivable of $0.7 million and $0.9 million included in prepaid expenses and other current assets as of March 31, 2022 and December 31, 2021, respectively. The Company has a long-term lease receivable of $0.6 million and $0.7 million included in other assets as of March 31, 2022 and December 31, 2021, respectively.
As of March 31, 2022, estimated future maturities of sales-type lease receivables for each of the following years are as follows (in thousands):
Nine months ending December 31, 2022$637 
Year ending December 31, 2023434 
Year ending December 31, 2024253 
Year ending December 31, 202550 
Year ending December 31, 2026 
Lease receivable$1,374 
Note 7—Property and Equipment, Net
The Company’s property and equipment, net, consisted of the following as of March 31, 2022 and December 31, 2021 (in thousands):
March 31,
December 31,
Medical diagnostic equipment$17,330 $16,759 
Furniture and fixtures433 433 
Office equipment1,573 1,538 
Laboratory equipment and software5,320 5,302 
Leasehold improvements580 582 
Construction in process1,083 958 
Total property and equipment26,319 25,572 
Less: accumulated depreciation(13,357)(11,902)
Property and equipment, net$12,962 $13,670 
Property and equipment includes certain medical diagnostic equipment, AcQMap Systems, located at customer premises. The Company retains ownership of the equipment and has the right to remove the equipment if it is not being used according to

expectations. The Company expenses the cost of the equipment when it is subsequently sold or enters into a sales-type lease agreement. See also Note 6—Lessor Sales-Type Leases above.
Depreciation expense was $1.6 million and $1.2 million for the three months ended March 31, 2022 and 2021, respectively. For the three months ended March 31, 2022 and 2021, the Company determined that there was no impairment of property and equipment.
Note 8—Goodwill and Intangible Assets
The table below summarizes goodwill and intangible assets activities as of March 31, 2022 and December 31, 2021 (in thousands):
Balance, December 31, 2021$12,026 $5,013 
Amortization expense— (160)
Goodwill impairment(12,026)— 
Balance, March 31, 2022 (unaudited)$ $4,853 

During the first quarter of 2022, the Company experienced a significant decline in stock price which reduced the market capitalization below the carrying value of the Company. The Company performed a quantitative assessment of the fair value of its reporting unit. The assessment used a combination of quoted market prices as well as present value calculations which included both the income and market approach. Based on the assessment, the Company concluded that the fair value of the reporting unit was less than its carrying amount in an amount that resulted in the Company fully impairing its goodwill balance of $12.0 million during the three months ended March 31, 2022.

(in years)
(in years)
March 31,
Developed technology10.07.3$4,200 $